Alivus Life Sciences Ltd. (GLS) — BSE Stock Analysis

Sector: Healthcare. Industry: Drug Manufacturers - Specialty & Generic. Share price: ₹1166.15.

Company Overview

Glenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Nirma Limited.

Valuation Snapshot

Market cap: —
P/E: —
P/B: —
ROE: —

Blanket Finance is not a SEBI-registered investment adviser or research analyst. This content is for educational and informational purposes only.